<DOC>
	<DOCNO>NCT00520481</DOCNO>
	<brief_summary>This single arm , multicenter , open-label , phase II study enroll chemotherapy-naive patient metastatic , histologically-confirmed adenocarcinoma prostate ( stage M1 D2 ) . Treatment continue evidence disease progression , intolerable toxicity , withdrawal criterion meet . Non-surgically castrated patient must continue use LHRH agonists protocol treatment .</brief_summary>
	<brief_title>Study With IMC-A12 ( Cixutumumab ) Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer</brief_title>
	<detailed_description>Thirty-one chemotherapy-naїve patient asymptomatic metastatic androgen-independent prostate cancer enrol treat I.V . IMC-A12 ( Cixutumumab ) 10 mg.kg administer 1 hour every 2 week . An additional 10 patient enrol treated IMC-A12 dose 20 mg/kg every three week . Treatment continue evidence disease progression intolerable toxicity . Radiographic evaluation response perform every 8 week patient treat I.V . IMC-A12 20 mg/kg .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Inclusion Criteria The patient male least 18 year age The patient histologicallyconfirmed adenocarcinoma prostate The patient radiographic evidence metastatic prostate cancer ( stage M1 [ D2 ] ) The patient prostate cancer unresponsive refractory hormone therapy The patient must evidence progressive disease define least one following : . Progressive measurable disease : use conventional solid tumor criterion . b . Bone scan progression : least one new lesion bone scan . c. Increasing PSA : least two consecutive rise PSA value reference value ( PSA # 1 ) take least 1 week apart . A third PSA ( PSA # 3 ) require great PSA # 2 ; , fourth PSA ( PSA # 4 ) require great PSA # 2 The patient PSA ≥ 2 ng/mL The patient receive prior chemotherapy metastatic prostate cancer The patient prior surgical medical castration serum testosterone level &lt; 50 ng/mL . If method castration luteinizing hormonereleasing hormone ( LHRH ) agonists , patient must willing continue use LHRH agonists protocol treatment All clinically significant toxic effect ( exclude alopecia ) prior surgery , radiotherapy , hormonal therapy resolve grade ≤ 1 base National Cancer Institute Common Terminology Criteria Adverse Events , Version 3.0 ( NCICTCAE ) The patient receive antiandrogen therapy least 6 week ( 4 week flutamide ) prior study entry without evidence antiandrogen withdrawal response . For patient whose progression document solely PSA increase , recent PSA value enable study entry must draw require antiandrogen washout period The patient Eastern Cooperative Oncology Group performance status ( ECOG PS ) 01 The patient adequate organ function include : absolute neutrophil count ≥ 1500/μL ; platelet ≥ 100,000/μL ; hemoglobin ≥ 9.0 g/dL ; bilirubin ≤ 1.5 time institutional upper limit normal ( ULN ) ; aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤ 3 time ULN ( &lt; 5x ULN liver metastasis present ) ; creatinine ≤ 1.5 x ULN ( calculate creatinine clearance &gt; 60 mL/min ) ; urine protein ≤ 1+ ( urine protein ≥ 2+ , 24hour urine collection must demonstrate &lt; 1000 mg protein 24 hour allow participation study ) The patient fast serum glucose &lt; 120 mg/dL ULN The patient adequate coagulation function define international normalized ratio ( INR ) ≤ 1.5 partial thromboplastin time ( PTT ) ≤ 1.5 ULN ( unless oral anticoagulant therapy ) . Patients receive fulldose anticoagulation therapy eligible provide meet criterion , stable dose oral anticoagulant low molecular weight heparin ( warfarin therapeutic INR 2 3 ) The patient asymptomatic prostate cancer . Patients minimal , infrequent cancerrelated symptom eligible . Criteria regard pain analgesic use detail The patient life expectancy &gt; 6 month The patient , sexually active , agree use contraceptive study The patient provide sign informed consent Exclusion Criteria The patient active malignancy ( adequately treat nonmelanomatous skin cancer noninvasive situ neoplasm ) , adequatelytreated prior cancer disease free &lt; 3 year The patient ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia ( wellcontrolled atrial fibrillation permit ) , psychiatric illness/social situation , active bleed pathological condition carry high risk bleeding ( eg , tumor involve major vessel , tumor invade rectal lumen , know varix ) , serious uncontrolled medical disorder opinion investigator The patient know hypersensitivity therapeutic protein product The patient know suspected brain leptomeningeal metastases The patient receive radiotherapy ≤ 21 day prior first dose IMCA12 The patient receive prior radiation therapy &gt; 30 % bone marrow prior strontium89 , rhenium186 , rhenium188 , samarium153 ( patient receive standard dose radiation pelvis prostate cancer additional radiotherapy eligible ) The patient know human immunodeficiency virus infection acquire immunodeficiency syndromerelated illness The patient receive one course radiotherapy single site metastatic bony disease The patient bone scan indicate `` superscan '' ( ie , extensive metastasis bone numerous area , numerous count define ) The patient receive corticosteroid ( dexamethasone , prednisone , others ) anorexia , weight loss , analgesia cancerrelated symptom ( Corticosteroids may institute patient begin therapy onstudy The patient require ongoing , regularly schedule opiate analgesic therapy cancer relate pain . Intermittent , infrequent lowpotency opiateuse ( eg , oxycodone , codeine ) permit The patient history prior treatment agent specifically target IGF receptor</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>